Changes to NICE influenza treatment guidance

NICE has updated its guidance on the treatment of influenza following a review of the use of amantadine, oseltamivir and zanamivir.

The revised guidance includes three key changes:

  • The addition of people with chronic liver disease or chronic neurological conditions to the list of ‘at risk' groups.*
  • The recommendation that zanamivir be considered as a treatment option for children aged five to 12 years in ‘at risk' groups provided that influenza is circulating and they can start treatment within 36 hours of first symptoms.
  • The recommendation that oseltamivir and zanamivir are now treatment options for ‘at-risk' people in long-term residential or nursing homes during localised outbreaks (when influenza is not circulating), if there is a high level of certainty that the causative agent is influenza.

*Other at-risk groups defined in the guidance include those with chronic respiratory, heart or renal disease or diabetes mellitus, those aged 65 years or over and those who may be immunosuppressed.

A summary of the new guidance is available at www.mims.co.uk. To read the full guidance visit the NICE website.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases